Search

everythinglearnresearchcommunity

for

Search:↓

DHA-NLC may improve drug delivery and reduce side effects for cancer treatment.

Nanotechnology is improving drug delivery and targeting, with promising applications in cancer treatment, gene therapy, and cosmetics, but challenges remain in ensuring precise delivery and safety.

The hydromethanolic extract of Carthamus caeruleus L. rhizome is a strong antioxidant and can kill cancer cells.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Some cosmetic ingredients can harm health, causing issues like allergies, cancer, and skin problems.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

Certain astrocytes can protect the brain and improve recovery after a stroke, and a hair loss drug might reduce cancer spread.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

AS101 reduces hair loss from chemotherapy.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Biomedical imaging has greatly improved understanding and treatment of solid tumors.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Radiological findings help distinguish LAM, PLCH, and BHD to avoid invasive tests.

Erlotinib can cause nonscarring hair loss and itchy skin.

Gefitinib can cause hair and eyebrow darkening.

Scalp cooling may be less effective for women of color on certain chemotherapy treatments.

Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.

Gefitinib therapy can cause unusual hair growth on the nose.

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

Erlotinib can cause hair loss and texture changes.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

Erlotinib can cause persistent excessive hair growth.

Erlotinib may cause scarring hair loss.

Erlotinib can cause hair loss as a side effect.

Reducing gefitinib dosage improved hair loss, but scarring remained.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

Stereotactic body radiation therapy and radiosurgery are advanced, precise treatments that target tumors while protecting healthy tissue.